Mutual of America Capital Management LLC Purchases 10,726 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Mutual of America Capital Management LLC increased its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 5.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 212,691 shares of the specialty pharmaceutical company’s stock after buying an additional 10,726 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Supernus Pharmaceuticals were worth $6,704,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of SUPN. Robeco Institutional Asset Management B.V. purchased a new position in Supernus Pharmaceuticals in the 1st quarter worth approximately $267,000. Meritage Portfolio Management raised its holdings in shares of Supernus Pharmaceuticals by 22.0% during the first quarter. Meritage Portfolio Management now owns 58,803 shares of the specialty pharmaceutical company’s stock valued at $1,926,000 after acquiring an additional 10,622 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of Supernus Pharmaceuticals by 3.2% during the first quarter. Principal Financial Group Inc. now owns 306,322 shares of the specialty pharmaceutical company’s stock valued at $10,032,000 after acquiring an additional 9,590 shares in the last quarter. Retirement Planning Co of New England Inc. raised its holdings in shares of Supernus Pharmaceuticals by 30.7% during the first quarter. Retirement Planning Co of New England Inc. now owns 28,000 shares of the specialty pharmaceutical company’s stock valued at $917,000 after acquiring an additional 6,573 shares in the last quarter. Finally, GW&K Investment Management LLC raised its holdings in shares of Supernus Pharmaceuticals by 14.6% during the first quarter. GW&K Investment Management LLC now owns 1,382,441 shares of the specialty pharmaceutical company’s stock valued at $45,275,000 after acquiring an additional 176,091 shares in the last quarter.

Insider Activity

In other news, SVP Frank Mottola sold 5,000 shares of the company’s stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $45.87, for a total transaction of $229,350.00. Following the completion of the sale, the senior vice president owned 15,496 shares of the company’s stock, valued at $710,801.52. This represents a 24.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Jack A. Khattar sold 59,900 shares of the company’s stock in a transaction dated Thursday, October 9th. The shares were sold at an average price of $50.57, for a total transaction of $3,029,143.00. Following the sale, the chief executive officer directly owned 1,206,578 shares of the company’s stock, valued at $61,016,649.46. The trade was a 4.73% decrease in their position. The disclosure for this sale can be found here. Insiders sold 362,741 shares of company stock valued at $16,390,592 in the last quarter. 8.80% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

SUPN has been the subject of a number of recent analyst reports. Wall Street Zen downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, October 8th. Zacks Research raised Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 17th. Piper Sandler raised Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $40.00 to $65.00 in a research note on Thursday, October 9th. Finally, Cantor Fitzgerald upped their price target on Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 30th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Supernus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $64.00.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ:SUPN opened at $51.59 on Tuesday. The stock’s fifty day moving average price is $46.12 and its 200-day moving average price is $37.45. The company has a market cap of $2.89 billion, a P/E ratio of 44.86 and a beta of 0.78. Supernus Pharmaceuticals, Inc. has a 1 year low of $29.16 and a 1 year high of $52.15.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.